Christy Wong

Associate
Norton Rose Fulbright Hong Kong
christy.wong@nortonrosefulbright.com
Christy
Wong
Christy Wong
Hong Kong SAR
38/F Jardine House
1 Connaught Place
Central
Hong Kong SAR
+852 34052576

Christy Wong is a corporate lawyer based in Hong Kong. She has extensive commercial and corporate finance experience, with a particular focus on initial public offerings, mergers and acquisitions, and regulatory and compliance matters for listed companies.

Representative experience

IPO / Listing

  • Breton Technology (1333.HK): H-share Main Board IPO and global offering. Represented CICC and CMB International.
  • Shandong Boan Biotechnology (6955.HK): H-share spin-off listing. Represented UBS and Essence International, now known as SDICSI.
  • Butong Group (6090.HK): Main Board IPO and global offering. Represented CITIC Securities and Haitong.
  • Hanx Biopharmaceuticals (Wuhan) (3378.HK): H-share Main Board listing under Chapter 18A of the Listing Rules and global offering. Represented ICBC International.
  • Tage iDriver: proposed H-share Main Board listing. A1 application filed. Represented Huatai International.

Annual Retainer

  • China Qidian Guofeng (1280.HK)
  • Inkeverse (3700.HK)
  • Mobvista (1860.HK)
  • NagaCorp (3918.HK)
  • Zhejiang Expressway (0576.HK)

Other Relevant Experence

  • China Dongxiang (3818.HK): Off-market buy-back of 256,090,025 shares, representing approximately 4.34% of the company’s total issued share capital. The buy-back formed part of a comprehensive settlement arrangement between the company and certain current and former members of management in connection with its previous share incentive schemes.
  • China Qidian Guofeng (1280.HK): Loan capitalization involving issuance of HK$185.50 million shares under specific mandate and application for a whitewash waiver.

Admissions

  • qualified in Hong Kong

Languages

  • English
  • Cantonese
  • Mandarin Chinese
Bio